Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing

Executive Summary

OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer

You may also be interested in...

Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B

Tarceva Price Will Be In Bounds, OSI Says: Above Iressa, Below Gleevec

Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said

Avastin, Erbitux Costs Invite Price Controls, Former NCI Deputy Says

The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts